2. UroToday Home
  3. Categories
  4. Conferences

AUA 2014

auaAmerican Urological Association (AUA)
Annual Meeting
May 16 - 21, 2014

Orlando, Florida USA

#AUA14 - Nadir testosterone on ADT predicts for time to castrate resistant progression: A secondary analysis of the PR-7 intermittent vs continuous ADT trial - Session Highlights

ORLANDO, FL USA (UroToday.com) - The NCIC/SWOG/UKCCR PR7 study randomized patients with biochemical failure after radiation or surgery plus radiation and no metastases between continuous life long androgen deprivation and intermittent androgen deprivation.

#AUA14 - Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort - Session Highlights

ORLANDO, FL USA (UroToday.com) - Prostate cancer biomarkers have tremendous potential to influence decisions regarding treatment and active surveillance. The CCP (cell cycle progression) score is a 46-gene expression level biomarker already known to be a robust predictor of prostate cancer outcomes.

#AUA14 - An exploratory analysis of the Genomic Prostate Score as a predictor of local or metastatic progression in men who experience biochemical recurrence after surgery for organ-confined prostate cancer - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Magi-Galluzzi’s group re-analyzed their radical prostatectomy (RP) cohort (127 patients with and 374 without clinical recurrence (CR)) to evaluate if GPS predicts CR after biochemical recurrence (BCR) and also to assess the impact of salvage therapies.

#AUA14 - Validation of a genomic classifier for predicting clinical progression following post-operative radiation therapy in high-risk prostate cancer - Session Highlights

ORLANDO, FL USA (UroToday.com) - In patients with high-risk prostate cancer (PC), radiation therapy (RT) is frequently offered following prostatectomy, but response rates vary.

#AUA14 - Variation of serum prostate-specific antigen levels for men with prostate cancer managed with active surveillance - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Behfar Edhaie, from Memorial Sloan Kettering Cancer Center, presented an abstract on whether isolated changes in PSA levels among men under active surveillance (AS) should be used as an indication for reclassification biopsy.

#AUA14 - Free serum testosterone versus total testosterone as surrogate marker for the clinical benefit of androgen suppression in prostate cancer patients - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Lucas Regis presented an institutional series on whether free serum testosterone (FT) or total testosterone (TT) can be a surrogate marker for the clinical benefit of androgen suppression in prostate cancer patients.

#AUA14 - An indirect treatment comparison and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer post chemotherapy - Session Highlights

ORLANDO, FL USA (UroToday.com) - The objective of this multi-institutional study was to determine the comparative effectiveness and cost-effectiveness of abiraterone acetate (AA) versus enzalutamide (ENZ).

#AUA14 - Impact of prior endocrine therapy on clinical benefit of abiraterone acetate in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Fred Saad presented a multi-institutional, exploratory analysis to evaluate the effect of prior endocrine therapy on clinical benefit of abiraterone (AA) in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) in the randomized phase III study, COU-AA-302.

#AUA14 - Efficacy and long-term safety analysis of study COU-AA-302: Abiraterone acetate plus prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Neal Shore presented an abstract on a multi-institutional study evaluating the safety and tolerability of long-term treatment (≥ 24 months) and also reported on the efficacy at 56% overall survival (OS) events of study COU-AA-302.

#AUA14 - Sipuleucel-T-induced antigen spread: immune response to prostate-specific antigen correlates with improved overall survival - Session Highlights

ORLANDO, FL USA (UroToday.com) - Sipuleucel-T is a prostatic acid phosphatase-targeting immunotherapy approved for treatment of asymptomatic or minimally symptomatic, metastatic castration-resistant prostate cancer (mCRPC).

Page 3 of 18